Global Patent Index - EP 1244356 A4

EP 1244356 A4 20030319 - COMPOSITIONS AND METHODS FOR L-NUCLEOSIDES, L-NUCLEOTIDES, AND THEIR ANALOGS

Title (en)

COMPOSITIONS AND METHODS FOR L-NUCLEOSIDES, L-NUCLEOTIDES, AND THEIR ANALOGS

Title (de)

ZUSAMMENSETZUNGEN UND VERFAHREN ZUR HERSTELLUNG VON L-NUCLEOSIDEN, L-NUCLEOTIDEN UND IHREN ANALOGA

Title (fr)

COMPOSITIONS ET PROCEDES RELATIVES A DES NUCLEOSIDES-L, A DES NUCLEOTIDES-L AINSI QU'A LEURS ANALOGUES

Publication

EP 1244356 A4 20030319 (EN)

Application

EP 00988189 A 20001219

Priority

  • US 0034605 W 20001219
  • US 17209799 P 19991223
  • US 17344699 P 19991229
  • US 17511100 P 20000106
  • US 19075800 P 20000320
  • US 22694700 P 20000822
  • US 22687500 P 20000822
  • US 23382100 P 20000919
  • US 23382300 P 20000919
  • US 23354800 P 20000919
  • US 23382200 P 20000919
  • US 23546500 P 20000926

Abstract (en)

[origin: WO0145509A1] Nucleoside and nucleotide compounds and their analogs/prodrugs are provided. Particularly contemplated compounds include 1- beta -L-ribofuranosyl-1,2,4-triazole-3-carboxamide, which may be modified and/or phosphorylated. Contemplated compounds may further be combined with other pharmacological compounds, especially including Ribavirin, antibodies, and cytokines. Preferred uses of contemplated compounds include use as an antiviral compound, anti-inflammatory compound, antineoplastic compound, and as a compound to stimulate cellular growth.

IPC 1-7

A01N 43/04; A61K 31/70; C07H 19/00; C07H 19/04; C07H 19/044; C07H 19/056; A61K 39/42

IPC 8 full level

C07H 19/056 (2006.01); A01N 43/72 (2006.01); A61K 31/70 (2006.01); A61K 31/7056 (2006.01); A61K 38/21 (2006.01); A61K 39/395 (2006.01); A61K 45/00 (2006.01); A61P 1/16 (2006.01); A61P 25/00 (2006.01); A61P 31/12 (2006.01); A61P 31/16 (2006.01); A61P 31/18 (2006.01); A61P 37/02 (2006.01); A61P 43/00 (2006.01); C07H 19/12 (2006.01)

IPC 8 main group level

A61P 29/00 (2006.01); A61P 35/00 (2006.01)

CPC (source: EP KR)

A01N 43/72 (2013.01 - EP); A61K 31/70 (2013.01 - EP); A61K 31/7056 (2013.01 - EP); A61K 39/395 (2013.01 - EP); A61P 1/16 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 29/00 (2017.12 - EP); A61P 31/12 (2017.12 - EP); A61P 31/16 (2017.12 - EP); A61P 31/18 (2017.12 - EP); A61P 35/00 (2017.12 - EP); A61P 37/02 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C07H 19/056 (2013.01 - KR); C07H 19/12 (2013.01 - EP)

C-Set (source: EP)

  1. A61K 31/70 + A61K 2300/00
  2. A61K 31/7056 + A61K 2300/00
  3. A61K 39/395 + A61K 2300/00

Citation (search report)

  • [X] WO 9204381 A1 19920319 - SCOTGEN LTD [GB]
  • [Y] WO 9816186 A2 19980423 - ICN PHARMACEUTICALS [US], et al
  • [X] US 3798209 A 19740319 - WITKOWSKI J, et al
  • [XY] EP 0956861 A1 19991117 - SCHERING CORP [US]
  • [XY] WO 8705807 A1 19871008 - GRUBER HARRY EDWARD
  • [XPY] WO 0030656 A1 20000602 - SALK INST FOR BIOLOGICAL STUDI [US], et al
  • [Y] EP 0707855 A2 19960424 - SCHERING CORP [US]
  • [XY] J. BALZARINI, C.K. LEE, P. HERDEWIJN, E. DE CLRECQ: "Mechanism of the potentiating effect of Ribavirin on the activity of 2',3'-dideoxyinosine against human immunodeficient virus", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, no. 32, 1991, USA, pages 21509 - 21514, XP002227433
  • [XY] GIUSEPPINA DI STEFANO, CORRADO BUSI, ALESSANDRO MATTIOLI, LUIGI FIUME: "Selective Delivery to the Livre of Antiviral Nucleoside Analogs Coupled to a High Molecular Mass Lactosaminated Poly-L-Lysine and Administrated to Mice by Intramuscular Route", BIOCHEMICAL PHARMACOLOGY, vol. 49, no. 12, 1995, UK, pages 1769 - 1775, XP002227434
  • [X] ROBERTO FERNANDEZ-LARSSON, JEAN L. PATTERSON: "Ribavirin in an inhibitor of Human Immunodeficiency Virus Reverse Transcriptase", MOLECULAR PHARMACOLOGY, vol. 38, no. 6, 1990, USA, pages 766 - 770, XP009003959
  • [XY] GABRIELSEN, BJARNE ET AL: "Synthesis and antiviral evaluation of N-carboxamidine-substituted analogs of 1-.beta.-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine hydrochloride.", JOURNAL OF MEDICINAL CHEMISTRY (1992), 35(17), 3231-8, 1992, XP002227435
  • [X] JAHRLING P B ET AL: "ENHANCED TREATMENT OF LASSA FEVER BY IMMUNE PLASMA COMBINED WITH RIBAVIRIN IN CYNOMOLGUS MONKEYS", JOURNAL OF INFECTIOUS DISEASES, CHICAGO, IL, US, vol. 149, no. 3, 1 March 1984 (1984-03-01), pages 420 - 427, XP002030799, ISSN: 0022-1899
  • See references of WO 0145509A1

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)

WO 0145509 A1 20010628; AU 2442201 A 20010703; BR 0016162 A 20020813; CA 2384326 A1 20010628; CN 1420723 A 20030528; CZ 20022112 A3 20030514; EP 1244356 A1 20021002; EP 1244356 A4 20030319; HK 1049944 A1 20030606; HR P20020485 A2 20051031; HU P0300219 A2 20030628; HU P0300219 A3 20050728; IL 148514 A0 20020912; JP 2003523957 A 20030812; KR 20030032908 A 20030426; MX PA02006251 A 20030128; NO 20022969 D0 20020620; NO 20022969 L 20020620; NZ 517634 A 20040625; PL 364927 A1 20041227; SI 20976 A 20030228; SK 8612002 A3 20030304; YU 47802 A 20060303

DOCDB simple family (application)

US 0034605 W 20001219; AU 2442201 A 20001218; BR 0016162 A 20001219; CA 2384326 A 20001219; CN 00817416 A 20001219; CZ 20022112 A 20001219; EP 00988189 A 20001219; HK 03102255 A 20030328; HR P20020485 A 20020603; HU P0300219 A 20001219; IL 14851400 A 20001219; JP 2001546256 A 20001219; KR 20027008069 A 20020621; MX PA02006251 A 20001219; NO 20022969 A 20020620; NZ 51763400 A 20001219; PL 36492700 A 20001219; SI 200020047 A 20001219; SK 8612002 A 20001219; YU P47802 A 20001219